Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats

Cardiovascular Research

Volumn 77, Issue 1, 2008, Pages 44-53

  Baker, John E ^a,b   Su, Jidong ^a,b   Hsu, Anna ^a   Shi, Yang ^a   Zhao, Ming ^a   Strande, Jennifer L ^a   Fu, Xiangping ^a,b   Xu, Hao ^a   Eis, Annie ^a   Komorowski, Richard ^a   Jensen, Eric S ^a   Tweddell, James S ^a,b   Rafiee, Parvaneh ^a   Gross, Garrett J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CHILDREN S HOSPITAL OF WISCONSIN   (United States)

Author keywords

Infarction; Ischaemia; K ATP channel; Protein kinases; Thrombopoietin

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CLAMIKALANT; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 3; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; POTASSIUM CHANNEL; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; THROMBOPOIETIN; THROMBOPOIETIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVATION; ENZYME INHIBITION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE FUNCTION; HEMATOCRIT; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOLEMMA; THROMBOCYTE COUNT; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; JANUS KINASE 2; KATP CHANNELS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIAL STUNNING; RATS; RATS, SPRAGUE-DAWLEY; STAT3 TRANSCRIPTION FACTOR; THROMBOPOIETIN; TIME FACTORS;

EID: 38849176235     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvm026     Document Type: Article

References (24)

1. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. Circ Res 2004;95:125-134.
2. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P et al. Recombinant human erythropoietin protects the myocardium from ischaemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 2003;100:4802-4806.
3. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci USA 2003;100:11612-11617.
4. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999-1007.
5. Shi Y, Rafiee P, Su J, Pritchard K Jr, Tweddell J, Baker J. Acute cardioprotective effects of erythropoietin in infant rabbits are mediated by activation of protein kinases and potassium channels. Basic Res Cardiol 2004;99:173-182.
6. Rouleau C, Cui K, Feldman L. A functional erythropoietin receptor is necessary for the action of thrombopoietin on erythroid cells lacking c-mpl. Exp Hematol 2004;32:140-148.
7. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys 1999;368:421-428.
8. Shi Y, Baker JE, Zhang C, Tweddell JS, Su J, Pritchard KA Jr. Chronic hypoxia increases endothelial nitric oxide synthase generation of nitric oxide by increasing heat shock protein 90 association and serine phosphorylation. Circ Res 2002;91:300-306.
9. Baker JE, Konorev EA, Gross GJ, Chilian WM, Jacob HJ. Resistance to myocardial ischemia in five rat strains: is there a genetic component of cardioprotection? Am J Physiol Heart Circ Physiol 2000;278:H1395- H1400.
10. Baker J, Hsu A, Fu X, Kozik D, Tweddell J, Gross G. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action and mechanisms. J Cardiovasc Pharmacol 2007;49:337-345.
11. Patel HH, Fryer RM, Gross ER, Bundey RA, Hsu AK, Isbell M et al. 12-lipoxygenase in opioid-induced delayed cardioprotection: gene array, mass spectrometric, and pharmacological analyses. Circ Res 2003;92:676-682.
12. Baker JE, Holman P, Gross GJ. Preconditioning in immature rabbit hearts: role of KATP channels. Circulation 1999;99:1249-1254.
13. Drachman JG, Millett KM, Kaushansky K. Thrombopoietin signal transduction requires functional JAK2, not TYK2. J Biol Chem 1999;274:13480- 13484.
14. Gurney AL, Wong SC, Henzel WJ, de Sauvage FJ. Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation. Proc Natl Acad Sci USA 1995;92:5292-5296.
15. Rafiee P, Shi Y, Kong X, Pritchard K Jr, Tweddell J, Litwin S et al. Activation of protein kinases in chronically hypoxic infant human and rabbit hearts: role in cardioprotection. Circulation 2002;106:239- 245.
16. Rafiee P, Shi Y, Su J, Pritchard K Jr, Tweddell JS, Baker JE. Erythropoietin protects the infant heart against ischemia-reperfusion injury by triggering multiple signaling pathways. Basic Res Cardiol 2005;100:187-197.
17. Gross GJ, Peart JN. KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 2003;285:H921-H930.
18. Li K, Sung RY, Huang WZ, Yang M, Pong NH, Lee SM et al. Thrombopoietin protects against in vitro and in vivo cardiotoxicity induced by doxorubicin. Circulation 2006;113:2211- 2220.
19. Hanley PJ, Daut J. K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 2005;39:17-50.
20. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, Patel S, Reddy SP, Hoots WK et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997;126:673-681.
21. Gajewski JL, Rondon G, Donato ML, Anderlini P, Korbling M, Ippoliti C et al. Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization. Biol Blood Marrow Transplant 2002;8:550-556.
22. Linker C, Anderlini P, Herzig R, Christiansen N, Somlo G, Bensinger W et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant 2003;9:405-413.
23. Harada K, Tazunoki Y, Ide Y, Takeuchi A, Kawahara J, Suzuki T. Effects of pegylated recombinant human megakaryocyte growth and development factor on 5-fluorouracil-induced thrombocytopenia in balloon-injured rats. J Pharm Pharmacol 2000;52:321-325.
24. Ide Y, Harada K, Imai A, Yanagida M. PEG-rHuMGDF ameliorates thrombocytopenia in carboplatin-treated rats without inducing myelofibrosis. Int J Hematol 1999;70:91-96.